Document is current
Any future updates will be listed below
-
Authors
Sumanaweera, Dinithi https://orcid.org/0000-0003-4515-0988
Suo, Chenqu https://orcid.org/0000-0002-8813-0875
Cujba, Ana-Maria
Muraro, Daniele
Dann, Emma https://orcid.org/0000-0002-7400-7438
Polanski, Krzysztof https://orcid.org/0000-0002-2586-9576
Steemers, Alexander S. https://orcid.org/0000-0002-7162-7279
Lee, Woochan
Oliver, Amanda J.
Park, Jong-Eun https://orcid.org/0000-0002-1687-2423
Meyer, Kerstin B. https://orcid.org/0000-0001-5906-1498
Dumitrascu, Bianca https://orcid.org/0000-0001-8328-2354
Teichmann, Sarah A. https://orcid.org/0000-0002-6294-6366
- License Information
-
More Information
Article History
Received: 18 October 2023
Accepted: 12 July 2024
First Online: 19 September 2024
Competing interests
: S.A.T. is a scientific advisory board member of ForeSite Labs, OMass Therapeutics, QIAGEN, a co-founder and equity holder of TransitionBio and EnsoCell Therapeutics, a nonexecutive director of 10x Genomics and a part-time employee of GlaxoSmithKline. The remaining authors declare no competing interests.
